IQVIA Holdings Inc.
NYSE•IQV
CEO: Mr. Ari Bousbib
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2013-05-09
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
連絡先情報
時価総額
$27.95B
PER (TTM)
20.6
30.2
配当利回り
--
52週高値
$247.05
52週安値
$134.65
52週レンジ
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$4.36B+0.00%
直近4四半期の推移
EPS
$3.02+0.00%
直近4四半期の推移
フリーCF
$561.00M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth 5.9% 2025 Revenues reached $16.31B, growing 5.9% over 2024, driven by constant currency growth of 4.8% across segments.
R&D Backlog Expansion Contracted backlog for Research & Development Solutions grew to $32.7B by year-end 2025, expecting $8.3B conversion next twelve months.
Acquisition Investment Surge Investing cash used $2.31B in 2025, driven by $1.71B net cash deployed for strategic business acquisitions across all segments.
Diluted EPS Improvement Diluted EPS was $7.84 in 2025, marking an increase of $0.35 compared to the $7.49 reported in the prior year.
リスク要因
Contract Loss Potential Potential loss or delay of large contracts could adversely affect results due to 30 to 90 day termination notice provisions in R&D Solutions.
Data Supplier Dependency Reliance on numerous third-party data suppliers; restrictions or failures to adhere to quality standards could materially impact operating results.
Increased Restructuring Costs Incurred $105M in restructuring costs during 2025 due to ongoing global operations streamlining efforts expected to continue into 2026.
Evolving Privacy Regulations Evolving global data protection and privacy laws create compliance uncertainty, requiring additional security measures and potential expenditures.
見通し
Segment Reporting Update Updating segment reporting effective January 1, 2026, renaming TAS to Commercial Solutions and realigning Real-World offerings.
AI and Technology Focus Strategy centers on innovating through IQVIA Connected Intelligence leveraging Healthcare-grade AI capabilities for efficiency and insights.
Broader Marketplace Penetration Plan to expand offerings penetration to broader healthcare marketplace, serving payers, providers, governments, and NGOs.
Strategic Acquisition Growth Expect continued strategic acquisitions to strengthen value proposition across life sciences, payer, and provider sectors moving forward.
同業比較
売上高 (TTM)
$244.49B
$129.66B
$25.31B
粗利益率 (最新四半期)
90.5%
82.5%
67.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CAH | $51.08B | 30.8 | -58.9% | 15.5% |
| HLN | $44.67B | 22.3 | 9.4% | 26.4% |
| ALC | $37.69B | 38.6 | 4.4% | 16.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.5%
緩やかな成長
4四半期純利益CAGR
27.3%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし